NBIX fund manager activity
Neurocrine Biosciences, Inc · Nasdaq. Reported by 6 tracked fund managers in their 13F filings, Q3 2017 to Q2 2026.
Q2 2026
| Manager | Activity | Shares | Value | % of portfolio | Filed |
|---|
| Dodge & Cox Funds | Added | 5,584,707 | $941,218,594 | 0.49% | Aug 13, 2026 |
| Ken Fisher - Fisher Asset Management | Added | 135,104 | $22,769,751 | 0.01% | Aug 4, 2026 |
| Jeremy Grantham - GMO | Added | 72,430 | $12,206,990 | 0.03% | Aug 13, 2026 |
| Joel Greenblatt - Gotham Asset Management | Added | 371,568 | $62,622,213 | 0.15% | Aug 14, 2026 |
Q1 2026
| Manager | Activity | Shares | Value | % of portfolio | Filed |
|---|
| Dodge & Cox Funds | Trimmed | 5,461,037 | $719,437,014 | 0.40% | May 14, 2026 |
| Ken Fisher - Fisher Asset Management | Added | 122,226 | $16,102,051 | 0.01% | May 5, 2026 |
| Jeremy Grantham - GMO | Added | 35,626 | $4,693,369 | 0.01% | May 14, 2026 |
| Joel Greenblatt - Gotham Asset Management | Added | 360,136 | $47,444,317 | 0.15% | May 15, 2026 |
Older quarters